Eli Lilly的股票在收入丰厚、糖尿病和减重药物前景改善后上涨。 Eli Lilly's stock rose after strong earnings and upgraded outlook for diabetes and weight-loss drugs.

Eli Lilly的股价上升了4.9%, 因为Leerink Partners将股价升级为超优, Eli Lilly's stock rose 4.9% after Leerink Partners upgraded it to Outperform, citing strong financial results and robust sales of diabetes and weight-loss drugs like Mounjaro and Zepbound. 该公司报告了季度利,每股7.02美元和176亿美元的收入,同比增长53.9%,并提高了2025年全年利预测. The company reported a quarterly earnings beat, with $7.02 per share and $17.6 billion in revenue, up 53.9% year-over-year, and raised its full-year 2025 earnings guidance. 机构投资者持有82.53%的股份,而股票交易额约为923.35美元,高达52周,最高额为969.48美元,协商一致的“收购”评级为983.76美元。 Institutional investors hold 82.53% of shares, and the stock, trading around $923.35, has a 52-week high of $969.48 and a consensus "Moderate Buy" rating with a $983.76 target.